HuGE Literature Finder
|
Records 1-3
The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients.
Archives of medical science : AMS 2018 Oct 14 (6): 1416-1423. Belohlavkova Petra, Vrbacky Filip, Voglova Jaroslava, Racil Zdenek, Zackova Daniela, Hrochova Katerina, Malakova Jana, Mayer Jiri, Zak Pav |
A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.
Haematologica 2013 Sep 98 (9): 1407-13. Shinohara Yoshinori, Takahashi Naoto, Nishiwaki Kaichi, Hino Masayuki, Kashimura Makoto, Wakita Hisashi, Hatano Yoshiaki, Hirasawa Akira, Nakagawa Yasuaki, Itoh Kuniaki, Masuoka Hidekazu, Aotsuka Nobuyuki, Matsuura Yasuhiro, Takahara Sinobu, Sano Koji, Kuroki Jun, Hata Tomoko, Nakamae Hirohisa, Mugitani Atsuko, Nakane Takahiko, Miyazaki Yasushi, Niioka Takenori, Miura Masatomo, Sawada Kenic |
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
Cancer 2010 Nov . Tiribelli M, Geromin A, Michelutti A, Cavallin M, Pianta A, Fabbro D, Russo D, Damante G, Fanin R, Damiani D |
- Page last reviewed:Jul 30, 2019
- Page last updated:Dec 12, 2019
- Content source: